BIO Reveals 2022-23 Executive Committee Directors

main_img

At its recent convention, the first live one in 3 years, the Biotechnology Innovation Organization (BIO) announced the Executive Committee directors for the 2022-2023 term, elected during the event that brought together global thought leaders for 4 days of interactive sessions.

This is a critical time for our industry. Our BIO Board – especially one as diverse and multi-faceted as this one – will help drive policies that keeps pace with innovation’s promise to cure disease, nourish society, and protect our planet.

Dr Michelle McMurry-Heath, President & CEO, BIO

 

The 2022-23 Executive Committee Directors are:

  • Paul Hastings, Nkarta Therapeutics – Board Chair/Health Section Chair
  • Elizabeth Lewis, Takeda Pharmaceuticals – Board Associate Vice Chair & Secretary
  • Bradford Zakes, Ceravast Medical – BIO Board Treasurer
  • Ted Love, Global Blood Therapeutics – Health Section Vice Chair
  • Sylvia Wulf, AquaBounty Technologies – Agriculture & Environment Section Chair
  • John Crowley, Amicus Therapeutics – Emerging Companies Section Chair
  • Jeremy Levin, Ovid Therapeutics – Immediate Past Chair
  • Erika Smith, ReNetX BIO – Emerging Companies Section Vice Chair
  • Anna Rath, Vestaron
  • Doug Doerfler, MaxCyte
  • Stuart Arbuckle, Vertex Pharmaceuticals
  • Christi Shaw, Kite, A Gilead Company
  • Bill Sibold, Genzyme, A Sanofi Company
  • Fritz Bittenbender, Genentech Roche
  • Chris Boerner, Bristol Myers Squibb
  • Eric Dube, Travere Therapeutics
  • Sue Washer, Applied Genetic Technologies Corporation (AGTC)
  • Aamir Malik, Pfizer
  • Jannie Oosthuizen, Merck
  • Victor Bulto, Novartis Pharmaceuticals
  • Bill Newell, Sutro BioPharma

Additional directors chosen as the Executive Advisory Board (EAB) to the Executive Committee:

  • Ron Cohen, AcordaTherapeutics
  • Rachel King, former BIO Board Chair
  • John Maraganore, former BIO Board Chair
  • Richard Pops, Alkermes

Newly Elected to the BIO Health Section Governing Board (2022-2025 Term):

  • Jannie Oosthuizen, Merck

Newly Elected to the BIO Emerging Companies Section Governing Board (2022-2023 Term):

  • Pablo Cagnoni, Rubius Therapeutics
  • Kaye Foster, The Boston Consulting Group
  • Mike Huckman, Real Chemistry
  • Elizabeth Jeffords, Iolyx Therapeutics
  • Sheila Mikhail, Asklepios BioPharmaceutical

Newly Elected to the BIO Agriculture and Environment Section Governing Board (2022-2024 Term):

  • Angela Ailloni, Ginkgo Bioworks
  • Rocco Morelli, Recombinetics

Related Content


Latest Report